Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial - Gilead Sciences
- Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial Gilead Sciences
- Gilead's twice-yearly shot cut HIV infections by 96% in trial CNBC
- Twice-a-year injection reduced risk of HIV infection by 96%, drug company says — more than daily PrEP pill CNN
- Gilead’s (GILD) Twice-Yearly Shot Prevents 96% of HIV Cases in Study Bloomberg